liver-targeted CRISPR/Cas9 gene therapy (Intellia/Regeneron)

N/A

Report date: 2025/01/26 18:05:45

Base Information

Drug Nameliver-targeted CRISPR/Cas9 gene therapy (Intellia/Regeneron)
Drug Alias Nameliver-targeted factor IX gene therapy (Intellia/Regeneron)
ClassificationBiologics
Mechanisms of ActionCoagulation factor IX modulators
TargetsCoagulation factor IX
Therapy Area/IndicationsHemophilia B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesIntellia Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesIntellia Therapeutics IncRegeneron Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsHemophilia B
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A